Sensex, Nifty at record highs; Burger King gains 131 per cent on listing debut, ONGC jumps 5 per cent, Adani Green declines
Sensex, Nifty at record highs; Burger King gains 131 per cent on listing debut, ONGC jumps 5 per cent, Adani Green declines

Sensex, Nifty at record highs; Burger King gains 131 per cent on listing debut, ONGC jumps 5 per cent, Adani Green declines

Geyatee Deshpande Article rating: 3.8

Markets ended close to record highs as Sensex gained by 154.45 points or by 0.34 per cent to settle at 46,253.46 levels while Nifty rose by 44.30 points or 0.33 per cent to close at 13,558.15 levels.

Cipla rises more than 4 per cent after settling over cancer drug Revlimid; earnings likely to boost
Cipla rises more than 4 per cent after settling over cancer drug Revlimid; earnings likely to boost

Cipla rises more than 4 per cent after settling over cancer drug Revlimid; earnings likely to boost

Deepti Shidore Article rating: 4.0

Cipla has settled its patent litigation with Celgene over the blockbuster cancer drug Revlimid. Celgene Corporation, a subsidiary of Bristol Myers Squibb, has agreed to provide Cipla with a licence to Celgene’s required patents. Cipla can then sell or manufacture certain volume-limited amounts of generic Lenalidomide in the United States sometime after March 2022.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

Ganesh Pawar Article rating: 3.6

The market opened in green on December 14, 2020, overall volumes in futures & options currently stand at 2,09,10,961 contracts with a turnover of Rs. 18,01,927.52 crore.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

Ganesh Pawar Article rating: 3.8

The market opened in green on December 14, 2020, overall volumes in futures & options currently stand at 2,09,10,961 contracts with a turnover of Rs. 18,01,927.52 crore.

European Commission expresses positive opinion on rapid-acting insulins of Biocon Biologics
European Commission expresses positive opinion on rapid-acting insulins of Biocon Biologics

European Commission expresses positive opinion on rapid-acting insulins of Biocon Biologics

Deepti Shidore Article rating: 5.0

A subsidiary of Biocon Limited i.e. Biocon Biologics and Mylan, a subsidiary of Viatris Inc., have received a positive opinion from European Medicines Agency's committee for medicinal products for human use (CHMP), recommending approval of the market authorisation of Kixelle, a biosimilar Insulin Aspart, which is rapid-acting insulin for the treatment of type 1 and 2 diabetes.

RSS
First23252326232723282330233223332334Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR